These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15144931)

  • 21. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
    Botoni FA; Poole-Wilson PA; Ribeiro AL; Okonko DO; Oliveira BM; Pinto AS; Teixeira MM; Teixeira AL; Reis AM; Dantas JB; Ferreira CS; Tavares WC; Rocha MO
    Am Heart J; 2007 Apr; 153(4):544.e1-8. PubMed ID: 17383291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
    Remme WJ; Torp-Pedersen C; Cleland JG; Poole-Wilson PA; Metra M; Komajda M; Swedberg K; Di Lenarda A; Spark P; Scherhag A; Moullet C; Lukas MA
    J Am Coll Cardiol; 2007 Mar; 49(9):963-71. PubMed ID: 17336720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    Fonarow GC; Abraham WT; Albert NM; Stough WG; Gheorghiade M; Greenberg BH; O'Connor CM; Sun JL; Yancy C; Young JB;
    Am Heart J; 2007 Jan; 153(1):82.e1-11. PubMed ID: 17174643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy.
    Doughty RN; Whalley GA; Walsh HA; Gamble GD; López-Sendón J; Sharpe N;
    Circulation; 2004 Jan; 109(2):201-6. PubMed ID: 14707020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H; Mohacsi P; Katus HA; Tendera M; Rouleau JL; Fowler MB; Coats AJ; Roecker EB; Packer M;
    Am Heart J; 2006 Jan; 151(1):55-61. PubMed ID: 16368292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program.
    Joglar JA; Acusta AP; Shusterman NH; Ramaswamy K; Kowal RC; Barbera SJ; Hamdan MH; Page RL
    Am Heart J; 2001 Sep; 142(3):498-501. PubMed ID: 11526364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carvedilol: use in chronic heart failure.
    Doughty RN; White HD
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carvedilol saves lives--new data from landmark trials prove survival benefits in heart failure and post myocardial infarction.
    Cardiovasc J S Afr; 2001; 12(2):122-3. PubMed ID: 11474697
    [No Abstract]   [Full Text] [Related]  

  • 33. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
    Munkhaugen J; Ruddox V; Halvorsen S; Dammen T; Fagerland MW; Hernæs KH; Vethe NT; Prescott E; Jensen SE; Rødevand O; Jortveit J; Bendz B; Schirmer H; Køber L; Bøtker HE; Larsen AI; Vikenes K; Steigen T; Wiseth R; Pedersen T; Edvardsen T; Otterstad JE; Atar D
    Am Heart J; 2019 Feb; 208():37-46. PubMed ID: 30530121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. a single-centre, randomized study of 232 patients.
    Jonsson G; Abdelnoor M; Müller C; Kjeldsen SE; Os I; Westheim A
    Cardiology; 2005; 103(3):148-55. PubMed ID: 15785019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
    Fowler MB
    Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol in severe heart failure.
    Fowler MB
    Am J Cardiol; 2004 May; 93(9A):35B-9B. PubMed ID: 15144935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
    Tatli E; Kurum T
    Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
    Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
    Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.